Volume 389, Issue 10087, Pages 2430-2442 (June 2017) Molecular alterations in triple-negative breast cancer—the road to new treatment strategies  Dr Carsten Denkert, MD, Cornelia Liedtke, MD, Andrew Tutt, MD, Gunter von Minckwitz, MD  The Lancet  Volume 389, Issue 10087, Pages 2430-2442 (June 2017) DOI: 10.1016/S0140-6736(16)32454-0 Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure Overview of relevant molecular alterations in triple-negative breast cancer Alterations are measured by different methodological approaches, including gene expression profiling, classical histopathology, and genomic alterations. Despite the different classification systems derived from different approaches, common themes are emerging. These include an increased immunological infiltrate (red), a high proliferation rate (green), the expression of androgen receptors (blue), and homologous recombination deficiency (orange). The colour-coding indicates that these themes are observed in parallel in different classification approaches. On the basis of these molecular results, at least four important therapy strategies for TNBC are emerging, which are currently being tested in clinical studies. HRD=homologous recombination deficiency. METABRIC=Molecular Taxonomy of Breast Cancer International Consortium. TCGA= the Cancer Genome Atlas. TILs=tumour-infiltrating lymphocytes. TNBC=triple-negative breast cancer. The Lancet 2017 389, 2430-2442DOI: (10.1016/S0140-6736(16)32454-0) Copyright © 2017 Elsevier Ltd Terms and Conditions